CSPC PHARMA (01093): CSPC Pharma's first quarter net loss attributable to parent company was 93.85 million yuan, a year-on-year increase of 248.88%.
China Resources Double-Crane Pharmaceutical Co., Ltd. (01093) announced that its subsidiary, China Resources Double-Crane Innovative Pharmaceuticals Co., Ltd. (CR Double-Crane Innovative), achieved operating income of 665 million yuan in the first quarter of 2026, a year-on-year increase of 40.82%. The net loss attributable to the shareholders of the listed company was 93.8547 million yuan, a year-on-year increase of 248.88%. The basic loss per share was 0.0674 yuan.
CSPC PHARMA (01093) announced that its subsidiary, Chiatai Tianqing Pharmaceutical Co., Ltd. (Chiatai Tianqing), achieved operating revenue of 665 million yuan in the first quarter of 2026, a year-on-year increase of 40.82%; The net loss attributable to the shareholders of the listed company was 93.8547 million yuan, an increase of 248.88% year-on-year; Basic loss per share was 0.0674 yuan.
Related Articles
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.
UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.
LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.
UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.
LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
